Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BEBT-109 is a potent selective inhibitor of pan-mutant EGFR with enhanced pharmacokinetic properties, suitable for research on various mutant-EGFR-driven non-small cell lung cancer (NSCLC) [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | BEBT-109 is a potent selective inhibitor of pan-mutant EGFR with enhanced pharmacokinetic properties, suitable for research on various mutant-EGFR-driven non-small cell lung cancer (NSCLC) [1]. |
Molecular Weight | 516.59 |
Formula | C27H32N8O3 |
CAS No. | 2050906-40-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BEBT-109 2050906-40-4 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR inhibitor inhibit